No Data
Kepler Capital Remains a Sell on Galapagos (0JXZ)
Cautious Hold Rating for Galapagos: Unproven Efficacy and Logistical Concerns in CD19 CAR-T Programs
Galapagos Announced New Results From Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma; Demonstrated High Antitumor Activity And An Encouraging Safety Profile In All NHL Subtypes...
Galapagos' Innovative CAR T-Cell Therapy Shows Promise
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)